In a groundbreaking development, the Georgia Board of Pharmacy has opened its doors to applications from nearly 120 pharmacies looking to provide medical marijuana products. This historic move makes Georgia the first state in the nation to permit the sale of low-dose cannabis within independent drug stores.

The implementation of the pharmacy rule, which extends medical marijuana sales to drug stores, promises to significantly enhance patient access. Up until now, the state has been served by only seven dispensaries, leaving patients with conditions such as Parkinson’s disease, seizures, terminal cancers, and PTSD with limited options.

The exclusive suppliers for these pharmacies will be the state’s only two licensed cannabis producers: Botanical Sciences LLC and Trulieve Cannabis Corp. These two companies were the first to receive approval earlier this year to cater to registered medical cannabis patients in Georgia.

Gary Long, CEO of Botanical Sciences, expressed his enthusiasm for this development, stating, “Pharmacists have been fielding questions from patients for years without ever having the ability to do anything about it. Finally, they have the ability not just to give people advice but provide them with the therapies they’ve been seeking.”

Georgia boasts more than 400 independent pharmacies, and the majority of them are expected to participate in this program. National chains such as CVS and Walgreens are the notable exceptions, as confirmed by Cecil Cordle, a member of the Georgia Board of Pharmacy.

This initiative is poised to bring convenience to the lives of Georgians, with approximately 90 percent of the state’s population residing within a 30-minute drive of a pharmacy offering medical marijuana products, according to reports.

Andrew Turnage, executive director for the Georgia Access to Medical Cannabis Commission, hailed the pharmacy rule as “definitely big news” and emphasized its benefits for both licensees and, most importantly, patients. He remarked, “It will put access in virtually every county in the state.”

Addressing the number of medical marijuana patients in Georgia, a recent revelation by the Georgia Department of Public Health stirred up some controversy. It was disclosed that the department had miscounted and overstated the count of registered medical marijuana patients. The accurate figure currently stands at just 14,000 active patients and caregivers, a far cry from the previously reported 50,000.

Source: Benzinga

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Cannabis Companies Launch Lawsuit Against Attorney General to Challenge Federal Prohibition

A coalition of cannabis businesses, represented by a prominent law firm, has initiated a long-awaited legal action against the U.S. attorney general. Their goal is to prevent the federal government from enforcing cannabis prohibition in states where it’s been legalized. These companies argue that maintaining prohibition in state-regulated markets is unconstitutional, endangering public safety and preventing licensed cannabis businesses from accessing essential financial services and tax benefits available to other industries.

Cannabis and Sports: A Complex Relationship Explored

The intersection of cannabis and sports has gained significant attention and scrutiny in recent years. Athletes across various disciplines are turning to cannabis for a range of reasons, including pain management, relaxation, and recovery. However, the relationship between cannabis and sports performance is a complex one, with both potential benefits and drawbacks that necessitate closer examination.

New Jersey Cannabis Regulators Propose New Permits to Facilitate Research Partnerships with Dispensaries

New Jersey’s cannabis regulatory authorities are currently open to public feedback regarding an innovative proposal aimed at introducing a novel permit. This permit would enable “clinically focused” dispensaries to collaborate with research institutions, facilitating comprehensive studies on cannabis using the products they cultivate and sell to patients.

Newsletter